130 related articles for article (PubMed ID: 23863262)
1. Features of massive hepatocellular carcinomas.
Carr BI; Guerra V
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):101-8. PubMed ID: 23863262
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma.
Carr BI; Guerra V; Pancoska P
Oncology; 2012; 83(6):339-45. PubMed ID: 23006937
[TBL] [Abstract][Full Text] [Related]
3. Low alpha-fetoprotein HCC and the role of GGTP.
Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F
Int J Biol Markers; 2014 Dec; 29(4):e395-402. PubMed ID: 24832180
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase.
Carr BI; Guerra V
Oncology; 2013; 85(3):153-9. PubMed ID: 23988857
[TBL] [Abstract][Full Text] [Related]
5. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.
Pang Q; Zhang JY; Xu XS; Song SD; Qu K; Chen W; Zhou YY; Miao RC; Liu SS; Dong YF; Liu C
World J Gastroenterol; 2015 May; 21(18):5607-21. PubMed ID: 25987786
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
7. Significance of platelet and AFP levels and liver function parameters for HCC size and survival.
Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Int J Biol Markers; 2014 Sep; 29(3):e215-23. PubMed ID: 24526315
[TBL] [Abstract][Full Text] [Related]
8. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
[TBL] [Abstract][Full Text] [Related]
9. Low alpha-fetoprotein hepatocellular carcinoma.
Carr BI; Pancoska P; Branch RA
J Gastroenterol Hepatol; 2010 Sep; 25(9):1543-9. PubMed ID: 20796153
[TBL] [Abstract][Full Text] [Related]
10. Significance of increased serum GGTP levels in HCC patients.
Carr BI; Pancoska P; Branch RA
Hepatogastroenterology; 2010; 57(101):869-74. PubMed ID: 21033244
[TBL] [Abstract][Full Text] [Related]
11. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization.
Dvorchik I; Carr BI
Cancer Detect Prev; 2007; 31(2):154-60. PubMed ID: 17416468
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
13. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
[TBL] [Abstract][Full Text] [Related]
14. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Ventura Y; Carr BI; Kori I; Guerra V; Shibolet O
World J Gastroenterol; 2018 Apr; 24(15):1641-1649. PubMed ID: 29686471
[TBL] [Abstract][Full Text] [Related]
15. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.
Hsu CY; Huang YH; Hsia CY; Su CW; Lin HC; Loong CC; Chiou YY; Chiang JH; Lee PC; Huo TI; Lee SD
J Hepatol; 2010 Jul; 53(1):108-17. PubMed ID: 20451283
[TBL] [Abstract][Full Text] [Related]
16. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
[TBL] [Abstract][Full Text] [Related]
17. HCC and its microenvironment.
Carr BI; Guerra V
Hepatogastroenterology; 2013 Sep; 60(126):1433-7. PubMed ID: 23933936
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma.
Lin CY; Kuo CS; Lu CL; Wu MY; Huang RF
Nutr Cancer; 2010; 62(2):190-7. PubMed ID: 20099193
[TBL] [Abstract][Full Text] [Related]
19. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival.
Kiriyama S; Uchiyama K; Ueno M; Ozawa S; Hayami S; Tani M; Yamaue H
Ann Surg; 2011 Dec; 254(6):984-91. PubMed ID: 21606837
[TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
